Cas No.: | 625375-83-9 |
Chemical Name: | 3-Quinolinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-, methanesulfonate, hydrate (1:2:3) |
Synonyms: | XR 9576;XR-9576;XR9576 |
SMILES: | O=C(NC1C(C(=O)NC2C=CC(CCN3CCC4C=C(C(=CC=4C3)OC)OC)=CC=2)=CC(OC)=C(OC)C=1)C1C=NC2C(=CC=CC=2)C=1.CS(=O)(O)=O.CS(=O)(O)=O.O.O.O |
Formula: | C40H52N4O15S2 |
M.Wt: | 892.9887 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A potent, specific P-gp inhibitor with Kd of 5.1 nM; potentiates the cytotoxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine in a panel of human MDR cell lines at 25-80 nM; exhibits potent i.v. and p.o. activity without apparently enhancing the plasma pharmacokinetics of paclitaxel or the toxicity of coadministered drugs.Breast CancerPhase 2 Discontinued |